A Study of a Candidate COVID-19 Vaccine (COV001)
NCT04324606 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1077
Last updated 2025-09-03
Summary
A phase I/II single-blinded, randomised, multi-centre study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers aged 18-55 years. The vaccine will be administered intramuscularly (IM) into the deltoid region of the arm
Conditions
- Coronavirus
Interventions
- BIOLOGICAL
-
ChAdOx1 nCoV-19
A single dose of 5x10\^10vp of ChAdOx1 nCoV-19
- BIOLOGICAL
-
MenACWY
Standard single dose of MenACWY vaccine delivered intramuscularly
- BIOLOGICAL
-
ChAdOx1 nCoV-19 full boost
A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 5x10\^10vp of ChAdOx1 nCoV-19
- BIOLOGICAL
-
ChAdOx1 nCoV-19 half boost
A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 2.5x10\^10vp of ChAdOx1 nCoV-19
- BIOLOGICAL
-
MenACWY boost
A standard dose of MenACWY followed by a boost dose of MenACWY
- DRUG
-
1g every 6 hours for 24 hours
- BIOLOGICAL
-
ChAdOx1 nCoV-19 0.5mL boost
A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp)
- BIOLOGICAL
-
ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV)
A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of 5x10\^10vp of ChAdOx1 nCoV-19
- BIOLOGICAL
-
ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT)
A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of MenACWY, then a boost 4-12 weeks later
Sponsors & Collaborators
-
University of Oxford
lead OTHER
Principal Investigators
-
Andrew Pollard, Prof · University of Oxford
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-04-23
- Primary Completion
- 2025-02-05
- Completion
- 2025-02-05
Countries
- United Kingdom
Study Locations
More Related Trials
-
A Study of Ad26.COV2.S in Adults (COVID-19)
NCT04436276 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Study of Recombinant Novel Coronavirus Vaccine
NCT04466085 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation
NCT04840992 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Ad26.COV2.S in Healthy Adults (COVID-19)
NCT04894305 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)
NCT04813562 ·Status: UNKNOWN ·Phase: PHASE2
-
An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older
NCT05679466 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
NCT04352608 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
NCT04652102 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above
NCT05664932 ·Status: UNKNOWN ·Phase: PHASE3
-
A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)
NCT04341389 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults
NCT04313127 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
NCT05602961 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers
NCT04295070 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
NCT04614948 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults
NCT04617483 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.
NCT05354089 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of Ad26.COV2.S in Adults (COVID-19)
NCT04509947 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers
NCT04773067 ·Status: TERMINATED ·Phase: PHASE2
-
To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.
NCT05351437 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above
NCT05408312 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
NCT05394012 ·Status: UNKNOWN ·Phase: PHASE1
-
Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)
NCT05323435 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Safety & Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19
NCT05102643 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.
NCT06255626 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
NCT04283461 ·Status: COMPLETED ·Phase: PHASE1